60 day Final

Federal Register / Vol. 71, No. 122 / Monday, June 26, 2006 / Notices
Character of the Service
Supplemental Reserve Service
(Supplemental Service) is needed to
serve load in the event of a system
contingency; however, it is not available
immediately to serve load.
Supplemental Service may be provided
by generating units that can be
synchronized to the system within 10
minutes and loaded within 30 minutes.
The transmission customer must either
purchase this service from the WALC
BATO, or make alternative comparable
arrangements satisfactory to Western to
meet its Supplemental Service
requirements. The charges for
Supplemental Service are referred to
below.
Formula Rate
Supplemental Service will not be
available from DSWR resources on a
long-term basis. If a customer cannot
self-supply or purchase this service
from another provider, Western may
obtain the Supplemental Service on a
pass-through cost basis at market price
plus a charge that covers the cost of
procuring and supplying the service.
The transmission customer will be
responsible for the transmission service
to get Supplemental Service to the
designated point of delivery.
Cost for Supplemental Service =
market price + cost to procure service.
[FR Doc. E6–10000 Filed 6–23–06; 8:45 am]
BILLING CODE 6450–01–P

rwilkins on PROD1PC63 with NOTICES

Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of

21:02 Jun 23, 2006

Jkt 208001

Board of Governors of the Federal Reserve
System, June 21, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E6–10018 Filed 6–23–06; 8:45 am]
BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention

FEDERAL RESERVE SYSTEM

VerDate Aug<31>2005

Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than July 21, 2006.
A. Federal Reserve Bank of Chicago
(Patrick M. Wilder, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690-1414:
1. Ohnward Bancshares Inc.,
Maquoketa, Iowa; to acquire 100 percent
of the voting shares of United Security
Financial Corporation, Cedar Rapids,
Iowa, and thereby indirectly acquire
United Security Savings Bank, F.S.B.,
Cedar Rapids, Iowa, and thereby engage
in operating a savings association,
pursuant to section 225.28(b)(4)(ii) of
Regulation Y.

[60Day-06–06BI]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Seleda Perryman,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
[email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have

PO 00000

Frm 00030

Fmt 4703

Sfmt 4703

36343

practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Determining Stakeholder Awareness
and Use of Products Developed by the
Evaluation of Genomic Applications in
Practice and Prevention (EGAPP)
Project—New—National Center for
Chronic Disease Prevention and Health
Promotion (NCCDPHP)/Office of
Genomics and Disease Prevention
(OGDP) Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The success of the Human Genome
Project has led to increasingly rapid
translation of genomic information into
clinical applications. Genetic tests for
about 1,200 diseases have been
developed, with more than 900
currently available for clinical testing.
Most are used for diagnosis of rare
genetic diseases, but a growing number
have population-based applications,
including carrier identification,
predictive testing for inherited risk for
common diseases, and pharmacogenetic
testing for variation in drug response.
These tests have the potential for broad
public health impact. Currently, most
genetic testing offered in the United
States does not involve the use of U.S.
Food and Drug Administration (FDA)
approved test kits. Tests are developed
as in-house or ‘‘home brew’’ assays and
marketed by laboratories as clinical
laboratory services with limited
oversight. A number of issues have been
raised about the current status of genetic
testing implementation, including the
need to develop evidence to establish
efficacy and cost-effectiveness before
tests are commercialized. There is also
an increasingly urgent need for timely
and reliable information that allows
health professionals to distinguish
genetic tests that have demonstrated
validity and utility in clinical practice.
Recommendations on the
development of safe and effective
genetic tests have been produced by
advisory panels (e.g. Task Force on
Genetic Testing, Secretary’s Advisory
Committee on Genetic Testing),
professional organizations, and clinical
experts since 1995. However, a

E:\FR\FM\26JNN1.SGM

26JNN1